Condition: Atherosclerotic Cardiovascular Disease · Sponsor: Novartis Pharmaceuticals
This non-randomized, rollover extension study will provide post-trial access to pelacarsen (TQJ230) to participants who have successfully completed either of the double-blind parent studies (CTQJ230A12303 or CTQJ230A12304).
This description comes directly from the study's public registry record.
Novartis Pharmaceuticals · 1-888-669-6682 · novartis.email@novartis.com
Novartis Pharmaceuticals · +41613241111
Always discuss trial participation with your own doctor first.
| Parkway Medical Center | Birmingham, Alabama, United States | Recruiting |
| Cardiology and Medicine Clinic PA | Little Rock, Arkansas, United States | Recruiting |
| National Heart Institute | Beverly Hills, California, United States | Recruiting |
| Hope Clinical Research | Canoga Park, California, United States | Recruiting |
| Valley Clinical Trials Inc | Covina, California, United States | Recruiting |
| NICRs Research Center | Garden Grove, California, United States | Recruiting |
| University of Calif Irvine Med Cntr | Irvine, California, United States | Recruiting |
| Long Beach Clinical Trials | Long Beach, California, United States | Recruiting |
| Angel City Research Inc | Los Angeles, California, United States | Recruiting |
| California Medical Research Associates Inc | Northridge, California, United States | Recruiting |
| Stanford Health Care | Stanford, California, United States | Recruiting |
| Excel Medical Clinical Trials LLC | Boca Raton, Florida, United States | Active Not Recruiting |
+ 85 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06875973